Novartis AG (NVS)


NYSE - NYSE Real Time Price. Currency in USD
78.77-0.57 (-0.72%)
At close: 4:02 PM EDT
People also watch:
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open78.72
Prev Close79.34
Bid78.74 x 100
Ask78.89 x 200
Day's Range78.36 - 78.82
52wk Range69.90 - 98.95
1y Target EstN/A
Market Cap187.57B
P/E Ratio (ttm)28.12
Beta0.64
Volume1,498,326
Avg Vol (3m)1,454,812
Dividend & Yield2.72 (3.41%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble
    Investor's Business Daily8 hours ago

    Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble

    Novartis' trimming of its CAR-T program, along with a gloomy initiation report on Kite Pharma, hit investor confidence.

  • Barrons.com11 hours ago

    Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?

    Quoting a letter sent to 400 staffers at the drug maker, Endpoints reported today that Novartis (NVS) is disbanding its pioneering cell and gene therapy unit, and folding it into other parts of the company. As the letter penned by Usman “Oz” Aman,” the Novartis executive who over saw the high-profile unit, read, “the risk of embarking on a new adventure in uncharted territory is that things don’t always work out as envisioned.” The news is having little impact on Novartis shareholders. As Piper Jaffrey analyst Joshua Schimmer and his team wrote today: For the broader autologous CAR-T field, we struggle with the implications of Novartis' move.

  • Bloomberg13 hours ago

    Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

    Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment....